Glucagon Rewritten: A Fat-Burning Ally in Disguise

Key Takeaway: In the Phase 3 SYNCHRONIZE-1 trial, survodutide, a first-in-class dual agonist targeting both glucagon and GLP-1 receptors, achieved up to 13% body weight loss in adults with obesity over 76 weeks. Its unique mechanism, which engages the glucagon receptor to increase energy expenditure in addition to suppressing appetite, positions survodutide as a distinct and powerful new weapon in the fight against obesity.

A New Player Enters the Scene

For decades, the pharmacological treatment of obesity was a graveyard of failed promises, filled with drugs that were ineffective, dangerous, or both. Then came agents like semaglutide and tirzepatide, which fundamentally shifted how the medical community thinks about weight management. Now, a new dual-action injection called survodutide has shown it can help individuals with obesity lose an average of 13% of their body weight, and it does so through a mechanism unlike any drug currently on the market. These results, from a large-scale Phase 3 clinical trial, herald a new chapter in obesity medicine—one that may involve a hormone most clinicians have long dismissed as simply a blood sugar-raising agent.

A Closer Look at the SYNCHRONIZE-1 Study

The SYNCHRONIZE-1 study enrolled 725 adults without diabetes but with obesity (defined as a body mass index of 30 or greater, or 27 or greater with at least one weight-related complication). Participants were randomly assigned to receive weekly subcutaneous injections of two different doses of survodutide (3.6 mg or 6.0 mg) or a placebo for 76 weeks.

The results were significant. At the 76-week mark, participants receiving the 3.6 mg dose lost an average of 12.2% of their body weight, while those on the 6.0 mg dose lost 13.0%. This was compared to a loss of only 5.4% in the placebo group (P<0.001 for both comparisons)^[1]. To put these figures in perspective, for a person weighing approximately 240 pounds (about 110 kg), the high dose corresponds to a loss of roughly 31 pounds (about 14 kg) over a year and a half.

In terms of clinically meaningful thresholds, 72.6% of participants in the 3.6 mg group and 71.9% in the 6.0 mg group achieved at least a 5% body weight loss, compared to 46.3% in the placebo group. These are the kinds of numbers that move the needle on metabolic health; a 5% to 10% reduction in body weight is consistently associated with improvements in blood pressure, blood sugar, and cholesterol levels^[2].

As expected with this class of medication, gastrointestinal side effects were common. Between 80.9% and 89.7% of participants taking survodutide reported symptoms like nausea, vomiting, or diarrhea, compared to 47.9% in the placebo group. While most of these cases were classified as mild to moderate, the high incidence is a clinical reality that will shape prescribing decisions.

The Mechanism: Why Glucagon is a Game-Changer

What makes survodutide truly unique is its dual receptor engagement. Today’s popular obesity drugs work on the incretin system; semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors^[3]. Survodutide takes a completely different path, pairing GLP-1 receptor activation with glucagon receptor activation.

GLP-1 receptor agonism is familiar territory. When GLP-1 receptors in the brain’s hypothalamus and brainstem are stimulated, appetite decreases. The stomach empties more slowly, making meals feel more satiating for longer. These effects are the foundation of the current generation of weight-loss medications^[4].

But the glucagon component is where things get interesting and counterintuitive. Glucagon is traditionally taught as the hormone that raises blood sugar by signaling the liver to release stored glucose. To give a drug that activates glucagon to promote weight loss seems paradoxical at first glance. But glucagon does much more than manage glucose. It is a potent stimulator of lipid oxidation in the liver—essentially telling the liver to burn fat for fuel. It also increases resting energy expenditure, meaning the body burns more calories even at rest^[5]. By combining this thermogenic, fat-burning signal with the appetite-suppressing effects of GLP-1, survodutide attacks obesity from two distinct physiological angles: reducing energy intake and increasing energy expenditure.

This dual mechanism has particularly intriguing implications for metabolic-associated steatotic liver disease (formerly non-alcoholic fatty liver disease), which affects roughly a quarter of the global adult population^[6]. By directly promoting fat oxidation in the liver via the glucagon receptor, it’s conceivable that survodutide could offer liver-specific benefits that pure GLP-1 agonists cannot match. This view, however, requires proof. Early-phase data in patients with liver steatosis are promising, and dedicated liver-focused studies are underway.

Limitations to Consider

No single study, however large, tells the whole story. SYNCHRONIZE-1 excluded individuals with diabetes, so we cannot yet generalize these results to this critical population. While the 76-week duration is notable, it doesn’t answer questions about weight regain after discontinuation, a well-documented phenomenon with GLP-1-based therapies^[7]. The high rate of gastrointestinal adverse events, though mostly mild to moderate, may limit tolerability in real-world practice where patients are monitored less closely than in a clinical trial. Furthermore, head-to-head trials against semaglutide and tirzepatide are not available, so ranking these agents against one another remains speculative without direct comparative data.

Conclusion: Implications for the Future

The results of SYNCHRONIZE-1 firmly establish survodutide as a practice-changing addition to obesity pharmacotherapy. An average weight loss of 13% at 76 weeks places it solidly among the most effective anti-obesity drugs studied to date, and its unique glucagon-mediated mechanism offers something that current drugs do not: a direct metabolic boost to energy expenditure and hepatic fat clearance.

For patients, this means the landscape of effective obesity treatments is deepening, not plateauing. For clinicians, it signals the dawn of an era of personalized obesity medicine—of matching a drug’s mechanism to a patient’s specific metabolic profile. A patient with prominent fatty liver, for example, may benefit from survodutide’s glucagon activity in ways a pure GLP-1 agonist cannot replicate. The gastrointestinal side effect burden will require frank conversations, but for many patients, a weight loss of over 30 pounds in 18 months may well justify the trade-off. The armamentarium against obesity has gained a genuinely new class of weapon, and that is a major win for the field.

Scientific Sources

1. le Roux CW, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine. 2026;395(8):776-787. PubMed: https://pubmed.ncbi.nlm.nih.gov/42253238/
2. Wing RR, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011. DOI: 10.2337/dc10-2415
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. DOI: 10.1056/NEJMoa2206038
4. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018. DOI: 10.1016/j.cmet.2018.03.001
5. Habegger KM, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010. DOI: 10.1038/nrendo.2010.187
6. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016. DOI: 10.1002/hep.28431
7. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14725